ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

被引：0
|
作者：
Flinn, Ian W.
Jacobson, Caron Alyce
Nastoupil, Loretta J.
Morschhauser, Franck
Davies, Andrew
Buske, Christian
Corradini, Paolo
Guillermo, Armando Lopez
Reshef, Ran
Parameswaran, Vinod
Sehgal, Alison
Tees, Michael Timothy
Lui, Christine
Xue, Wei
Beygi, Sara
Grechko, Nikolay
Bolsue, Pisita
Giovanetti, Alessandro
To, Christina Ann
Nahas, Myrna
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Lille, Ctr Hosp Univ, Lille, France
[5] Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England
[6] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Univ Barcelona, Barcelona, Spain
[9] Columbia Univ, Med Ctr, New York, NY USA
[10] Avera Med Grp Hematol Transplant & Cellular Thera, Sioux Falls, SD USA
[11] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[12] Colorado Blood Canc Inst, Denver, CO USA
[13] Kite, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7579
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
  • [2] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
    Oluwole, Olalekan O.
    Bishop, Michael R.
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Dolores Caballero, Maria
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294
  • [3] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
  • [4] ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
    Oluwole, Olalekan O.
    Bishop, Michael Russell
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Barrigon, Maria Dolores Caballero
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul C.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Chaganti, Sridhar
    Cwynarski, Kate
    Cunningham, David
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Radford, John
    Westin, Jason R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
  • [6] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    Van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    BLOOD, 2021, 138
  • [7] Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Dreger, P.
    Westin, J.
    Oluwole, O.
    Kersten, M. J.
    Miklos, D.
    Perales, M. -A
    Ghobadi, A.
    Rapoport, A.
    Sureda, A.
    Jacobson, C.
    Farooq, U.
    van Meerten, T.
    Ulrickson, M.
    Elsawy, M.
    Leslie, L.
    Chaganti, S.
    Dickinson, M.
    Yang, Y.
    Schupp, M.
    To, C.
    Locke, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 271 - 272
  • [8] A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma
    Bachy, Emmanuel
    Neelapu, Sattva S.
    Chavez, Julio C.
    Yakoub-Agha, Ibrahim
    Lui, Christine
    Wulff, Jacob
    Miao, Harry
    Nikolajeva, Olga
    Best, Timothy
    Linot, Camille
    Jacobson, Caron A.
    BLOOD, 2023, 142
  • [9] Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
    Jacobson, Caron
    Chavez, Julio C.
    Sehgal, Alison R.
    William, Basem M.
    Munoz, Javier
    Salles, Gilles
    Munshi, Pashna N.
    Casulo, Carla
    Maloney, David
    De Vos, Sven
    Reshef, Ran
    Leslie, Lori A.
    Yakoub-Agha, Ibrahim
    Oluwole, Olalekan O.
    Fung, Henry C. H.
    Rosenblatt, Joseph D.
    Rossi, John M.
    Goyal, Lovely
    Plaks, Vicki
    Yang, Yin
    Lee, Jennifer
    Godfrey, Wayne
    Vezan, Remus
    Avanzi, Mauro P.
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [10] Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)
    Jacobson, Caron A.
    Chavez, Julio C.
    Sehgal, Alison R.
    William, Basem M.
    Munoz, Javier
    Salles, Gilles
    Casulo, Carla
    Munshi, Pashna N.
    Maloney, David G.
    de Vos, Sven
    Reshef, Ran
    Leslie, Lori A.
    Yakoub-Agha, Ibrahim
    Oluwole, Olalekan O.
    Fung, Henry C.
    Plaks, Vicki
    Yang, Yin
    Lee, Jennifer
    Avanzi, Mauro P.
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S278 - S278
12345